Kleiner Perkins Caufield & Byers (KPCB) is a venture capital firm specializing in investments in incubation, seed stage, early stage, growth capital, expansion capital, and later stage companies. The firm seeks to invest in green technology innovation, biotechnology, medical, information technology, digital enterprises, media, telecommunication, consumer, pandemic and bio-defense, life sciences, digital health, smart grid, lighting, wind, industrial efficiency, low-carbon solutions to transportation, chemicals, power generation, infrastructure markets and services, internet, financial services, educational software, consumer internet, digital technology including social, mobile, and e-commerce sectors. Within pandemic and bio-defense, it invests in surveillance, diagnostics, vaccines, antiviral drugs, and technologies enabling large-scale manufacturing. Within life science sector, the firm invests in medical devices, therapeutics, tools and services, drugs, vaccines, personalized medicine, diagnostics, and healthcare information technology and services. They invests globally focusing on China. Kleiner Perkins Caufield & Byers was founded in 1972 and is based in Menlo Park, California with additional offices in San Francisco, California; Shanghai, China; and Beijing, China.